

## **Examining Challenges to Antibiotic Commercialization in International Markets**

1201 Pennsylvania Ave NW, Suite 500 • Washington, DC

November 6, 2019 • 11:30 am – 5:00 pm

### **Participant List**

**Bruce Altevogt**

Vice President and Head, External Medical Engagement, Hospital Business Unit, Pfizer Inc.

**Luciana Borio**

Vice President, Technical Staff, In-Q-Tel

**Rick Bright**

Director, Biomedical Advanced Research and Development Authority (BARDA)

**Steve Conafay**

Principal & Founder, The Conafay Group/  
Antimicrobials Working Group

**Robert DeVol**

Executive Director, Strategy & Market Access, Tetrphase Pharmaceuticals, Inc.

**John Farley**

Acting Director, Office of Antimicrobial Products, U.S. Food and Drug Administration

**Greg Frank**

Director, Infectious Disease Policy, Biotechnology Innovation Organization (BIO)

**Ray Frost**

Vice President Market Access and Health Policy, Melinta Therapeutics

**Marc Gitzinger**

Vice President, BEAM Alliance (and CEO, BioVersys AG)

**Marianne Hamilton Lopez**

Research Director, Duke-Margolis Center for Health Policy

**Nicholas Harrison**

Senior Research Assistant, Duke-Margolis Center for Health Policy

**Jenny Hellman**

Analyst, Public Health Agency of Sweden

**Chris Henshall**

Independent Consultant and Visiting Fellow, Office of Health Economics (UK)

**Silas Holland**

Director, Global Public Policy, Merck & Company, Inc.

**Robert Horne**

Principal, Leavitt Partners

**Brenda Huneycutt**

Director, Regulatory Innovation, FasterCures

**Jayasree Iyer**

Executive Director, Access to Medicines Foundation

**Amber Jessup**

Senior Advisor, Office of the Assistant Secretary for Planning and Evaluation

**Wes Kim**

Senior Officer, Innovation, The Pew Charitable Trusts

**Eric Kimble**

Chief Commercial Officer, Entasis

**Jeremy Knox**

Director of Policy, Drug Resistant Infections,  
Wellcome Trust

**Anthony Lakavage**

Senior Vice President, Global External Affairs,  
United States Pharmacopeia Convention

**Lynn Marks**

Senior Advisor, Tunnell Government Services

**Mark McClellan**

Director, Duke-Margolis Center for Health Policy

**Tyler Merkeley**

DRIVE Director (Acting), Biomedical  
Advanced Research and Development Authority  
(BARDA)

**Gareth Morgan**

Senior Vice President Portfolio Management,  
Shionogi & Co., Ltd.

**Elizabeth Murphy**

Project Coordinator, Duke-Margolis Center for  
Health Policy

**Sumathi Nambiar**

Director of the Division of Anti-Infective  
Products, Office of Antimicrobial Products, U.S.  
Food and Drug Administration

**Melinda Neuhauser**

Pharmacist and Acute Care Lead, Centers for  
Disease Control and Prevention

**Kevin Outterson**

Executive Director, CARB-X

**Jean-Pierre Paccaud**

Director, Business Development and Corporate  
Strategy, Global Antibiotic Research and  
Development Partnership (GARDP)

**David Payne**

Vice President Antibacterials, GlaxoSmithKline  
plc.

**John Rex**

Chief Medical Officer, F2G Ltd.  
Expert-in-Residence, Wellcome Trust

**David Ridley**

Dr. and Mrs. Frank A. Riddick Professor of the  
Practice of Business, Duke University

**Will Sargent**

Vice President, Commercial Strategy, Nabriva  
Therapeutics plc

**Jen Schneider**

Founder, The Ad Astra Team

**Monika Schneider**

Managing Associate, Duke-Margolis Center for  
Health Policy

**Sarah Sheehan**

Research Associate, Duke-Margolis Center for  
Health Policy

**Melissa Stundick**

Executive Director, Strategic Alliances, Spero  
Therapeutics, Inc.

**Adrian Thomas**

Vice President Public Health, Johnson &  
Johnson

**Emily Wheeler**

Project Manager, The Conafay Group/  
Antimicrobials Working Group

**Erin Wilhelm**

Director, Global External Affairs, United States  
Pharmacopeia Convention

**Marta Wosinska**

Deputy Directory, Policy, Duke-Margolis Center  
for Health Policy